

Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for <input type="text" value="Venous thromboembolism"/>
	Therapeutic equivalent to dabigatran for <input type="text" value="Other specified atrial fibrillation"/>

Dabigatran

Section	Indications
Medicines affecting coagulation Oral > Solid: 110 mg; 150 mg	<input type="text" value="Venous thromboembolism"/>
	<input type="text" value="Other specified atrial fibrillation"/>

Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to enoxaparin for <input type="text" value="Acute ischaemic heart disease"/>
	Therapeutic equivalent to enoxaparin for <input type="text" value="Venous thromboembolism"/>

Desmopressin

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate) Local > Nasal > Spray: 10 µg per dose (acetate)	<input type="text" value="Haemophilia A"/>
	<input type="text" value="Von Willebrand disease"/>

Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to dabigatran for <input type="text" value="Venous thromboembolism"/>
	Therapeutic equivalent to dabigatran for <input type="text" value="Other specified atrial fibrillation"/>

Enoxaparin

Section

Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

Acute ischaemic heart disease

Venous thromboembolism

Heparin sodium

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule

Indications

Acute ischaemic heart disease

Unstable angina

Venous thromboembolism

Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

Phytomenadione

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
Oral > Solid: 10 mg tablet

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Haemorrhagic or haematological disorders of fetus or newborn

Protamine sulfate

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

Tranexamic acid

Section

Medicines affecting coagulation

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Haemorrhage, not elsewhere classified

Warfarin

Section

Medicines affecting coagulation

Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt);
0.5 mg (sodium salt)

Indications

Other specified diseases of arteries or arterioles

Cerebral ischaemic stroke due to embolic occlusion

Venous thromboembolism

Atrial fibrillation